Procaps Group S.A. (PROC)
Market Closed
9 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
0. 03
0
0%
$
102.08M Market Cap
8.23 P/E Ratio
- Div Yield
383 Volume
0.15 Eps
$ 0.03
Previous Close Want to track PROC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Seekingalpha | 1 year ago
